Verastem, Inc.
VSTM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for VSTM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VSTM
Verastem, Inc. is a late-stage biopharmaceutical company focused on developing small molecule inhibitors targeting RAS and parallel signaling pathways in cancer, with a lead approved product AVMAPKI FAKZYNJA CO-PACK and a pipeline including avutometinib plus defactinib in Phase 3 trials.
Key risk: Clinical trial delays
BioSniper Score
Based on 6 of 6 signals
Market Cap
$653.9M
Cash Runway
10.1 moLead Asset
avmapki fakzynja co-pack (Approved)Next Catalyst
Phase3_Topline · Feb 9, 2031Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 15 clinical trials · 2 catalysts · 1 FDA decision for Verastem, Inc..
Verastem, Inc. is a late-stage biopharmaceutical company focused on developing small molecule inhibitors targeting RAS and parallel signaling pathways in cancer, with a lead approved product AVMAPKI FAKZYNJA CO-PACK and a pipeline including avutometinib plus defactinib in Phase 3 trials.
- Verastem's lead approved product is AVMAPKI FAKZYNJA CO-PACK, launched commercially in the U.S. in May 2025 [sec_mda · as of 2026-08-06].
- The company is advancing a Phase 3 pivotal trial (RAMP 301) of avutometinib plus defactinib in low-grade serous ovarian cancer (LGSOC), with potential to expand indication regardless of KRAS mutation status [sec_mda · as of 2026-03-04].
- As of June 30, 2026, Verastem reported cash, cash equivalents, and investments of $136.4 million [sec_mda · as of 2026-08-06].
- The pipeline includes clinical-stage programs targeting KRAS G12D, RAF/MEK, and FAK pathways, as well as preclinical and externally partnered early-stage programs [sec_mda · as of 2026-03-04].
- Verastem plans to enroll the first patient in each of three Phase 3 pivotal trials (first-line mPDAC, mCRC, advanced NSCLC) in the first half of 2027 [sec · filed 2026-06-23].
What works
- Verastem has an FDA-approved product (AVMAPKI FAKZYNJA CO-PACK) generating commercial revenue, providing a foundation for ongoing operations [sec_mda · as of 2026-08-06].
- The company's lead combination (avutometinib + defactinib) is in a Phase 3 registrational trial (RAMP 301) with potential for broad label expansion across KRAS mutation status [sec_mda · as of 2026-03-04].
- Verastem has a diversified pipeline targeting multiple RAS pathway nodes (KRAS G12D, RAF/MEK, FAK) and multiple tumor types [sec_mda · as of 2026-03-04].
- The company has collaboration and license agreements with partners such as Sanofi, CSPC, and Yakult, providing non-dilutive funding and milestone potential [sec_mda · as of 2026-08-06].
What to weigh
- Verastem reported a net loss of $34.7 million for the quarter ended June 30, 2026, indicating ongoing operating losses [latest reported financials].
- The company's accumulated deficit and reliance on future financing are significant; future capital requirements depend on many factors including clinical trial costs and commercialization expenses [sec_mda · as of 2026-03-04].
- The Phase 3 trials in first-line mPDAC, mCRC, and advanced NSCLC are still in early stages (first patient enrollment expected in first half of 2027), with no data yet [sec · filed 2026-06-23].
- Verastem faces typical biotech risks including regulatory approval uncertainty, clinical trial delays, and competition in the RAS-targeted therapy space [sec_mda · as of 2026-03-04].
From the filings
Quoted directly from source documents.
Verastem has an approved product AVMAPKI FAKZYNJA CO-PACK launched in May 2025.
“we have financed a portion of our operations through product revenue, including from AVMAPKI FAKZYNJA CO-PACK, beginning with our U.S. commercial launch in May 2025”
SEC MD&A · August 6, 2026
Cash position as of June 30, 2026.
“As of June 30, 2026, we had $136.4 million in cash, cash equivalents, and investments.”
SEC MD&A · August 6, 2026
Phase 3 RAMP 301 trial may support regulatory filings in Europe and Japan.
“Results of the RAMP 301 trial may also support future regulatory filings in Europe and Japan.”
SEC MD&A · March 4, 2026
Plan to enroll first patient in three Phase 3 trials in first half of 2027.
“Enroll the first patient in each of the Phase 3 pivotal trials in the first half of 2027.”
SEC filings · June 23, 2026
Catalyst timeline
- 2031-02-09 · Phase3_Topline — Topline data from the Phase 3 randomized open-label study of avutometinib plus defactinib; will inform potential regulatory submissions.
- 2042-12-29 · Patent_Expiry · AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) — Patent/exclusivity expiry for the approved co-packaged product; may affect market exclusivity and competitive landscape.
Risks & what to watch (4)›
Key risks
- Clinical trial delays — Phase 3 trials in mPDAC, mCRC, NSCLC are early; first patient enrollment expected H1 2027, with no data yet [sec · filed 2026-06-23].
- Regulatory approval uncertainty — Avutometinib/defactinib combination requires FDA approval; RAMP 301 results may not support label expansion [sec_mda · as of 2026-03-04].
- Commercial adoption risk — AVMAPKI FAKZYNJA CO-PACK is newly launched; revenue generation and market uptake are unproven [sec_mda · as of 2026-08-06].
- Financing dependency — Net loss of $34.7M in Q2 2026; future capital needs depend on milestones, partnerships, and equity/debt financing [sec_mda · as of 2026-03-04].
What to watch
- Enrollment initiation for Phase 3 trials in first-line mPDAC, mCRC, and advanced NSCLC, expected in first half of 2027 [sec · filed 2026-06-23].
- Data updates from the TARGET-D 101 trial expected in the second half of 2026 [sec · filed 2026-06-23].
- Regulatory interactions with the FDA regarding development path for PDAC and NSCLC, planned for first half of 2026 [sec_mda · as of 2025-11-04].
- Commercial ramp of AVMAPKI FAKZYNJA CO-PACK and its impact on revenue and cash runway [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Verastem, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Verastem, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
10.1 months
D/E 3.13 · 0% dilution
Lead: Approved
4 candidates
2 upcoming, next in ~1624d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
154
Total value held
$396.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,645,540 | $35.2M |
| rtw investments, lp | 6,576,306 | $34.9M |
| blackrock, inc. | 6,194,925 | $32.8M |
| deep track capital, lp | 5,740,850 | $30.4M |
| armistice capital, llc | 4,592,000 | $24.3M |
| state street corp | 3,516,651 | $18.6M |
| millennium management llc | 2,411,965 | $12.8M |
| citadel advisors llc | 2,376,269 | $12.6M |
| morgan stanley | 2,247,273 | $11.9M |
| rosalind advisors, inc. | 2,138,475 | $11.3M |
Showing top 10 of 154 institutional holders of Verastem, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 20.1%
- Days to cover
- 8.4
- Shares short
- 17,523,588
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VSTM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Verastem, Inc.?
Verastem, Inc. is a late-stage biopharmaceutical company focused on developing small molecule inhibitors targeting RAS and parallel signaling pathways in cancer, with a lead approved product AVMAPKI FAKZYNJA CO-PACK and a pipeline including avutometinib plus defactinib in Phase 3 trials.
What is Verastem, Inc.'s lead drug candidate?
Verastem, Inc.'s most advanced tracked candidate is avmapki fakzynja co-pack (Approved) for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).
What is Verastem, Inc.'s next catalyst?
Verastem, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver" — expected February 9, 2031.
Who is the CEO of Verastem, Inc.?
Mr. Daniel W. Paterson is the chief executive officer of Verastem, Inc. (VSTM).
Where is Verastem, Inc. headquartered?
Verastem, Inc. (VSTM) is headquartered in Needham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.